Trans-national Access call - June 2019
Specialised phenotyping pipelines
Call information and application forms
Context and aim of the call
INFRAFRONTIER is the European Research Infrastructure for phenotyping and archiving of model mammalian genomes. The INFRAFRONTIER Research Infrastructure provides access to first-class tools and data for biomedical research, and thereby contributes to improving the understanding of gene function in human health and disease using the mouse model. The core services of INFRAFRONTIER comprise the systemic and specialised phenotyping of mouse mutants in the participating mouse clinics, and the archiving and distribution of mouse mutant lines by the European Mouse Mutant Archive (EMMA).
In this specialised phenotyping call we provide access to a comprehensive panel of phenotyping tests, relying on standardized and customized protocols in key therapeutic areas:
) Induced secondary phenotyping screen under acute or more chronic inflammatory conditions
BIOMEDCODE - http://www.biomedcode.com/gr/en
BIOMEDCODE provides access to an induced secondary phenotyping screen under acute or more chronic inflammatory conditions. While primary phenotyping of mutant mouse lines can provide useful information on the involvement of genes in physiology, often their role in pathology can be only revealed when studied in a disease context or following a pathogenic trigger. Such a trigger can be for example inflammation, which has been implicated in a number of pathologic conditions. To uncover gene function in pathologic processes we offer a specialised phenotyping screen under inflammatory conditions. The proposed screen involves the phenotypic analysis of mutant animals combined with one acute and one chronic inflammatory model. The user’s research interests, the nature of the mutated gene and the strain of the mutant animal under investigation will dictate the selection of the most appropriate combination of one acute and one chronic model, to provide the most informative customized output for the user. Through this secondary screening of mutants under inflammatory and disease conditions, the user will be able to uncover the role of their mutant of interest in pathologic conditions.
2. ) Functional immune-phenotyping screen by mass cytometry
PHENOMIN-CIPHE / http://ciphe.marseille.inserm.fr/en/
The PHENOMIN-CIPHE mouse clinic provides access to its infrastructure and expertise for analysing mouse mutant lines through specialised functional immune-phenotyping by mass cytometry. To characterize the functional impact, on the immune system, of the invalidation or the overexpression of a gene of interest, cellular immune-phenotype profiling is required. This primary immunophenotyping screen, essentially based on an extracellular labelling, aims at quantifying the various cell populations present within a model by monitoring the expression of specific cell surface receptors in hematopoietic cells. This first approach describing cellular heterogeneity does not assess the effector functions of immune cells. To this end, a more functional secondary immune-phenotyping screen is required and offered in this call.
Access to the mouse clinics and their specialised phenotyping screens will be granted based on scientific excellence and supports the development and in-depth characterisation of mouse models for investigating gene function and human pathophysiology. INFRAFRONTIER will provide open access to all characterised disease models and phenotyping data.
Details of access modalities and call application forms: https://www.infrafrontier.eu/resources-and-services/infrafrontier-open-calls/specialised-phenotyping
Proposal submission to email@example.com
Rolling deadline – collecting applications at the 1st of every month
Proposal evaluation will start directly after the deadline for applications has passed.
The INFRAFRONTIER2020 project has received funding from the EU Research and Innovation programme Horizon 2020 (H2020-EU.18.104.22.168. Developing new world class research infrastructures)
www.infrafrontier.eu and https://twitter.com/InfrafrontierEU